BioMedNewsBreaks — BioAdaptives Inc. (BDPT) to Proceed with Human Clinical Trial for Zeranovia(TM)

BioAdaptives (OTC: BDPT) today announced its receipt of approval for a human clinical trial of its weight management product, Zeranovia(TM). Approved by an Institutional Review Board, the trial will be managed and supervised by doctors in Las Vegas, Nevada.

“According to data from the National Institutes of Health’s Office of Dietary Supplements (‘ODS’), less than 1.0% of nutraceuticals sold in the United States undergo examination in human clinical trials,” said BioAdaptives CEO James Keener. “We are committed to supplying the highest quality products with provable scientific results. Zeranovia’s(TM) success is based on a high-protein blend of vitamins, minerals, and five concentrated herbal supplements, four of which are adaptogens.”

To view the full press release, visit https://ibn.fm/281Mf

About BioAdaptives Inc.

BioAdaptives is a leader in the nutritional products industry, committed to delivering innovative solutions that enhance quality of life, anti-aging, cell repair, and well-being. With a deep focus on research, customer insights and sustainable practices, BioAdaptives is redefining what customers can expect from nutritional products. For more information, visit www.BioAdaptives.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN